-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $40

Benzinga·03/25/2026 10:27:57
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the price target from $25 to $40.